Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    ARCHAIC -hydroxychloroquine, 2020
     
    NL8490
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
    9/6 inconclusive
      CCAP-1, 2020
       
      NCT04345289
      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
      -/- inconclusive
        Chen, 2020
         
        NCT04384380
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        21/12 inconclusive
          Duke university HCQ, 2020
           
          NCT04335552
          RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
          4/2 no results
            discontinued, found in Axfors et al. meta-analysis
            HYCOVID, 2020
             
            NCT04325893
            RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
            124/123 inconclusive
            • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
            NO COVID-19 (Lyngbakken), 2020
             
            NCT04316377
            RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
            27/26 inconclusive
              OAHU-COVID19, 2020
               
              NCT04345692
              RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
              10/6 inconclusive
                ORCHID, 2020
                 
                NCT04332991
                RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
                242/237 inconclusive
                • inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
                RECOVERY, 2020
                 
                NCT04381936
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                1561/3155 safety concern
                • inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
                SOLIDARITY (WHO study) HCQ, 2020
                 
                NCT04315948
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                947/906 inconclusive
                • inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                Tang, 2020
                 
                ChiCTR2000029868
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
                75/75 safety concern
                • statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
                TEACH, 2020
                 
                NCT04369742
                RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
                67/61 inconclusive
                • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias
                Arshad (HCQ), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                1202/409 suggested
                • suggested 66 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                Belgian Collaborative Group on COVID-19, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                4542/3533 suggested
                • suggested 32 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
                Geleris, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                811/565 inconclusive
                  Magagnoli (HC), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                  97/158 safety concern
                  • safety concern with statistically significant 1.6-fold increase in deaths,deaths (time to event analysis only)
                  Novales, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                  123/43 suggested
                  • suggested 93 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
                  Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
                  38/46 inconclusive
                    Sbidian (HCQ alone), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                    623/3792 safety concern
                    • statistically significant 25 % increase in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                    Singh, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                    -/- inconclusive

                      COVID 19 all comers meta-analysis

                      ChiCTR2000030054-HCQ (Chen), 2020
                       
                      ChiCTR2000030054
                      RCThydroxychloroquinestandard of careCOVID 19 all comershigh
                      18/12 inconclusive
                        Gautret et al., 2020 NRahydroxychloroquinecontrolCOVID 19 all comersserious
                        20/16 suggested
                        • suggested 15.3-fold increase in PCR-negative conversion (PE) but with a low degree of certainty due to high risk of bias
                        a viral load reduction/disappearance is claimed but the numerous methological limits preclude any strong conclusion

                        COVID-19 mild to moderate meta-analysis

                        Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
                         
                        NCT04322123
                        RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                        221/227 safety concern
                        • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                        HC-nCoV (Shanghai), 2020
                         
                        NCT04261517
                        RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                        15/15 inconclusive
                          NCT04333654, 2020
                           
                          NCT04333654
                          RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
                          -/- inconclusive
                            Zhaowei Chen, 2020
                             
                            ChiCTR2000029559
                            RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
                            31/31 inconclusive
                              Zhaowei Chen, 2020
                               
                              ChiCTR2000029559
                              RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
                              31/31 suggested
                              • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
                              • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
                              Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
                              20/20 inconclusive

                                COVID-19 severe or critically meta-analysis

                                HYDRA, 2020
                                 
                                NCT04315896
                                RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
                                75/77 inconclusive
                                • inconclusive 1 % decrease in deaths (PE)
                                REMAP-CAP-HCQ, 2020
                                 
                                NCT02735707
                                RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
                                61/81 inconclusive
                                • inconclusive 4 % increase in deaths (PE)
                                REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
                                Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
                                84/97 inconclusive
                                  Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
                                  48/520 suggested
                                  • suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

                                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).